Saturday 17 October 2026
Export BRTX’s income statement to Excel — free account
Biorestorative Therapies, Inc.
BRTX Healthcare Biotechnology
Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024. In the quarter to March 2026, revenue fell 7.20%, EPS grew 81.3% and free cash flow fell 35.3%, each against the same quarter a year earlier.
1.54
0.08
+5.48%
Follow BRTX
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 4 | 3 |
| (137.34%) | (208.21%) | (321.48%) | (241.50%) | ||
| (87.06%) | (125.35%) | (174.11%) | (147.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(251.36%) | (801.27%) | 6,268.49% | (439.82%) | |
Average Days of Receivables |
9.05 | 12.76 | 15.73 | 13.56 | |
Free Cash Flow per Share |
(22.03) | (23.63) | (24.25) | (13.33) | |
Free Cash Flow |
(9.63) | (10.77) | (10.91) | (11.82) | |
Capital Expenditures |
(0.11) | (0.05) | (0.12) | — | |
| Other line items | |||||
Cash ROIC |
(78.74%) | (160.83%) | (329.50%) | (178.58%) | |
Accounts Receivable Turnover |
28.55 | 4.30 | 3.53 | 18.69 | |
Accounts Payable Turnover |
0.08 | 0.04 | 0.03 | 0.04 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
6,725.48 | 12,308.37 | 20,573.42 | 8,601.36 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,498.28% | 2,662.75% | 2,806.42% | 2,619.20% | |
Selling, General and Administrative Expense of Revenue |
759.15% | 1,215.68% | 1,637.00% | 1,447.56% | |
Share Based Compensation of Revenue |
485.41% | 796.43% | 924.55% | 448.92% | |
Interest Coverage |
21.44 | — | 28.78 | 52.36 | |
Operating CF/Net income |
0.89 | 0.85 | 0.76 | 1.07 | |
Depreciation/Fixed assets |
0.60 | 0.67 | 0.59 | 0.64 | |
Capex/Depreciation |
(0.53) | (0.24) | (0.55) | 0.00 | |
Revenue per Share |
1.38 | 0.84 | 0.80 | 0.40 | |
Operating CF per Share |
(21.79) | (23.52) | (23.99) | (13.33) | |
Capex per Share |
(0.25) | (0.11) | (0.26) | 0.00 | |
Capex to Sales |
0.18 | 0.13 | 0.32 | 0.00 |
Columns are period end dates